Loading...
Several studies have shown that ivermectin, an antiparasitic agent licensed to treat onchocerciasis and strongyloidiasis, has in vitro antiviral and anti-inflammatory properties — and reports have indicated clinical improvement with use of ivermectin in patients with COVID-19.
The COVID-19 Treatment Guidelines Panel's position is that data are insufficient to recommend for or against ivermectin's use. Key points underlying this statement are:
Most clinical trials had small sample sizes.
The dosages of ivermectin varied among studies and, in most, were markedly lower than required to achieve plasma levels mirroring the concentrations that enabled in vitro an…